Selective laser trabeculoplasty as secondary therapy in patients with glaucoma five year experience
This presentation is the property of its rightful owner.
Sponsored Links
1 / 11

Arusha Gupta, MD Elaine M. Miglino Lawrence F. Jindra, MD PowerPoint PPT Presentation


  • 99 Views
  • Uploaded on
  • Presentation posted in: General

SELECTIVE LASER TRABECULOPLASTY AS SECONDARY THERAPY IN PATIENTS WITH GLAUCOMA: FIVE-YEAR EXPERIENCE. Arusha Gupta, MD Elaine M. Miglino Lawrence F. Jindra, MD. Financial Disclosures. 1 st and 2 nd authors have no financial disclosure.

Download Presentation

Arusha Gupta, MD Elaine M. Miglino Lawrence F. Jindra, MD

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Selective laser trabeculoplasty as secondary therapy in patients with glaucoma five year experience

SELECTIVE LASER TRABECULOPLASTY AS SECONDARY THERAPY IN PATIENTS WITH GLAUCOMA: FIVE-YEAR EXPERIENCE

Arusha Gupta, MD

Elaine M. Miglino

Lawrence F. Jindra, MD


Financial disclosures

Financial Disclosures

1st and 2nd authors have no financial disclosure.

3rd author has independently conducted and financed clinical research study presented and provides technical advice and consultant services to Lumenis Corporation.


Introduction

Introduction

Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency-doubled (532 nm) Nd:YAG laser which targets melanocytes in the pigmented trabecular meshwork.1,2 When treated with SLT, a primarily biologic response is induced in the trabecular meshwork which involves the release of cytokines that trigger macrophage recruitment and other changes leading to IOP reduction.2It treats the meshwork without causing any thermal or coagulative damage to surrounding structures.1,2

1. Latina MA, et al. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and cw laser interactions. Exp Eye Res. 1995;60:359-372. 2. Latina MA, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105:2082-2090.


Objective and methods

Objective and Methods

To evaluate SLT as secondary therapy (eyes treated with medications) in decreasing intraocular pressure (IOP) and in reducing usage of glaucoma medication (meds) in patients with glaucoma.

A retrospective chart review was performed on 756 of 2056 eyes in a consecutive case series from patients treated with SLT as secondary therapy over 5 years between 2002 and 2007.Two-tailed paired t-test was used to compare maximum pre- and post-SLT IOP and pre- and post-SLT number of meds.


Results iop

Results: IOP

756 eyes received SLT as secondary treatment for glaucoma; mean follow-up time was 362 days.

IOP decreased from a mean of 20.0 mm Hg ± 6.0 to 15.8 mm Hg ±4.9. This represents a 21% decrease in IOP or 4.2 mm Hg.

Data were significant with P < 0.01.


Results meds

Results: Meds

Mean number of meds decreased from 2.3 to 1.3 meds; this represents a 43%decrease in meds used.

Success rate (no meds needed post-SLT) was 42% of eyes treated.

Data were significant with P < 0.01.


Data iop

Data: IOP


Data meds

Data: Meds


Results iop meds

Results: IOP & Meds


Summary

Summary

Mean Post-SLT reduction in:

IOP21%

Meds43%

The results were significant with P < 0.01.


Conclusion

Conclusion

In this clinical series, SLT significantly lowered intraocular pressure and the amount of medications required,when used as secondary treatment for glaucoma.


  • Login